NAME

Huijian Wu

Paper Publications

α-catenin SUMOylation increases IκBα stability and inhibits breast cancer progression
  • Hits:
  • Indexed by:

    期刊论文

  • First Author:

    Chen Huan

  • Co-author:

    Wang Miao,Wu Huijian,Xu Zhaowei,Li Xiahui,Yang Yangyang,Li Bowen,Li Yanan,Xia Kangkai,Wang Jian,Li Shujing

  • Date of Publication:

    2018-03-13

  • Journal:

    Oncogenesis

  • Included Journals:

    PubMed

  • Document Type:

    J

  • Volume:

    7

  • Issue:

    3

  • Page Number:

    28

  • ISSN No.:

    2157-9024

  • Abstract:

    α-catenin has been demonstrated to suppress several different types of cancers. Here we demonstrate that α-catenin is modified by SUMO protein, which covalently binds α-catenin at the carboxy terminus at lysine 870. Substitution of lysine 870 with arginine completely abolishes α-catenin SUMOylation. This modification can be removed by SENP1. However, α-catenin SUMOylation does not affect its stability and subcellular localization. In addition, we observed that the SUMOylation-deficient α-catenin mutant has a reduced interaction with IκBα which prevents subsequent ubiquitination of IκBα, and therefore a reduced suppression of expression of the NF-κB target genes TNF-α, IL-8, VEGF, and uPA. In addition, the α-catenin SUMOylation mutant shows impaired suppression of tumor growth. These results demonstrate that SUMOylation at lysine 870 of α-catenin plays a key role in the suppression of the NF-κB pathway, which inhibits breast cancer tumor growth and migration.

Pre One:Novel decellularized liver matrix-alginate hybrid gel beads for the 3D culture of hepatocellular carcinoma cells.

Next One:U-box ubiquitin ligase PPIL2 suppresses breast cancer invasion and metastasis by altering cell morphology and promoting SNAI1 ubiquitination and degradation.